Radiation dosimetry of 89Zr labeled antibody estimated using the MIRD method and MCNP code
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
One important issue in using radiopharmaceuticals as therapeutic and imaging agents is predicting different organ absorbed dose following their injection. The present study aims at extrapolating dosimetry estimates to a female phantom from the animal data of 89Zr radionuclide accumulation using the Sparks-Idogan relationship. The absorbed dose of 89Zr radionuclide in different organs of the human body was calculated based on its distribution data in mice using both MIRD method and the MCNP simulation code. In this study, breasts, liver, heart wall, stomach, kidneys, lungs and spleen were considered as source and target organs. The highest and the lowest absorbed doses were respectively delivered to the liver (4.00E-02 and 3.43E-02 mGy/MBq) and the stomach (1.83E-03 and 1.66E-03 mGy/MBq). Moreover, there was a good agreement between the results obtained from both MIRD and MCNP methods. Therefore, according to the dosimetry results, [89Zr] DFO-CR011-PET/CT seems to be a suitable for diagnostic imaging of the breast anomalies for CDX-011 targeting gpNMB in patients with TNBC in the future.
Abstract
One important issue in using radiopharmaceuticals as therapeutic and imaging agents is predicting different organ absorbed dose following their injection. The present study aims at extrapolating dosimetry estimates to a female phantom from the animal data of 89Zr radionuclide accumulation using the Sparks-Idogan relationship. The absorbed dose of 89Zr radionuclide in different organs of the human body was calculated based on its distribution data in mice using both MIRD method and the MCNP simulation code. In this study, breasts, liver, heart wall, stomach, kidneys, lungs and spleen were considered as source and target organs. The highest and the lowest absorbed doses were respectively delivered to the liver (4.00E-02 and 3.43E-02 mGy/MBq) and the stomach (1.83E-03 and 1.66E-03 mGy/MBq). Moreover, there was a good agreement between the results obtained from both MIRD and MCNP methods. Therefore, according to the dosimetry results, [89Zr] DFO-CR011-PET/CT seems to be a suitable for diagnostic imaging of the breast anomalies for CDX-011 targeting gpNMB in patients with TNBC in the future.
참고문헌 (18)
- A. A. Rose, "Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer", Clin. Cancer Res, 16(7), pp.2147~2156 (2010)
- A. A. Rose, "Osteoactivin promotes breast cancer metastasis to bone", Mol. Cancer Res, 5(10), pp.1001~1014 (2007)
- G. Maric, "Glycoprotein non-metastatic b(GPNMB) : A metastatic mediator and emerging therapeutic target in cancer", Onco Targets Ther, 6, pp.839~852 (2013)[DOI]
- D. A. Yardley, "EMERGE : a randomized phase II study of the antibodydrug conjugate glembatumumab vedotin in advanced glycoprotein NMBeexpressing breast cancer", J. Clin. Oncol, 33(14), pp.1609~1619 (2015)
- P. A. Ott, "Phase I", II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma, 2014, pp.32(32), 3659~
- V. A. Pollack, "Treatment parameters modulating regression of human melanoma xenografts by an antibodyedrug conjugate(CR011-vcMMAE)targeting GPNMB", Cancer Chemother. Pharmacol, 60(3), pp.423~435 (2007)
- X. Qian, "Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate", Molecular oncology, 2(1), pp.81~93 (2008)
- R. Hernandez, "ImmunoPET imaging of tissue factor expression in pancreatic cancer with 89Zr-Df-ALT-836", J. Contr. Release, 264, pp.160~168 (2017)
- B. V. Marquez-Nostra, "Preclinical PET imaging of glycoprotein nonmetastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent", Oncotarget, 8(61), pp.104303~ (2017)
- W. E. Bolch, "MIRD pamphlet no. 21 : a generalized schema for radiopharmaceutical dosimetrydstandardization of nomenclature", J. Nucl. Med, 50(3), pp.477~484 (2009)
- A. Khorrami Moghaddam, "Determination of human absorbed dose of 201Tl(III)-DTPA-HIgG based on biodistribution data in rats", Radiat. Protect. Dosim, 141(3), pp.269~274 (2010)
- Comparison of the Effectiveness of Some Common Animal Data Scaling Techniques in Estimating Human Radiation Dose, "R. Sparks", Oak Ridge Associated Universities, ~ (1999)
- S. Mattsson, "Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP publication 53. ICRP publication 106. Approved by the commission in October 2007", Ann. ICRP, 38(1-2), pp.1~197 (2008)
- Trastuzumab: Evaluation of radiation dosimetry, safety, and optimal imaging parameters in women with HER2-positive breast cance, "Mol. Imaging Biol", 2016, 952~959
- S. Shanehsazzadeh, "Estimation of human effective absorbed dose of 67GaecDTPAegonadorelin based on biodistribution rat data", Nucl. Med. Commun, 32(1), pp.37~43 (2011)
- M. Naserpour, "Estimation of human absorbed dose of 99mTc-MAA using MIRD method based on animal data and comparison with MCNP simulation code", Arch. Adv. Biosci, 12(1), pp.1~6 (2021)
- M. A. Deri, "PET imaging with 89Zr : from radiochemistry to the clinic", Nucl. Med. Biol, 40(1), pp.3~14 (2013)
- Y. Janjigian, "Positron emission tomography (PET) with 89Zr-labeled trastuzumab (89Zr-trastuzumab): Monitoring HER2 expression in HER2-positive gastric cancer in vivo", J. Clin. Oncol, 29(4_suppl), pp.35~35 (2011)